Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and chronic obstructive pulmonary disease (COPD). The Phase IV SPRINT study was conducted in 10 countries in Europe to assess asthma disease control and COPD symptom burden in patients treated with a fixed-dose combination (FDC) of inhaled corticosteroids (ICS) and long-acting beta agonists (LABAs). SPRINT included 1101 patients with asthma and 560 with COPD; all were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers. Data were obtained over a 3-month period, during a single routine physician's office visit. Asthma control was defined as Asthma Control Test (ACT) score >19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score <10 defining low COPD symptom burden. Among patients using any ICS/LABA FDC, 62% of patients with asthma had achieved disease control (ACT score >19) and 16% of patients with COPD had low symptom burden (CAT score <10).

中文翻译：

---

使用固定剂量联合吸入器的患者的哮喘控制和COPD症状负担（SPRINT研究）。

先前的研究发现，哮喘和慢性阻塞性肺疾病（COPD）患者普遍存在症状负担的欠佳控制。在欧洲的10个国家进行了IV期SPRINT研究，以评估用吸入剂量的糖皮质激素（ICS）和长效β受体激动剂（LABAs）固定剂量联合治疗（FDC）治疗的患者的哮喘疾病控制和COPD症状负担。SPRINT包括1101名哮喘患者和560名COPD患者；所有患者均接受通过各种吸入器输送的ICS / LABA FDC治疗。在单次常规医师就诊期间的三个月内获得了数据。哮喘控制定义为哮喘控制测试（ACT）得分> 19。通过COPD评估测试（CAT）评估COPD症状负担，CAT得分<10定义为低COPD症状负担。